PFE monthly performance report
Monthly PFE research: returns, drawdown, relative strength, seasonality, and key stats.
PFE monthly report
—
Key takeaways
- Pfizer (PFE) closed August 2026 at $25.81, up 3.20% for the month and +4.28% over the trailing 12 months.
- Year-to-date, PFE is +3.65%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading −0.18% versus its 200-day moving average ($25.86), a cautious technical signal.
- Over the past three years, PFE has underperformed the S&P 500 by −98.59%, with a relative strength index reading of 42.4.
- Win rate over the trailing 39 months stands at 38.5% — 15 positive months versus 24 negative months.
Pfizer ended August 2026 at $25.81, posting a monthly return of +3.20%. The S&P 500 returned +3.05% over the same window, leaving relative performance at +0.15%.
The current quarter stands at +6.75% (Q3 2026 (QTD)), while medium-term trend remains soft: price is −0.18% versus the 200-day moving average ($25.86).
Year-to-date, PFE is +3.65% against SPY +12.89%, a gap of −9.23%. The stock is currently −10.23% below its 52-week high, with maximum 3-year drawdown at −41.66%.
| Period | PFE | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +1.57% | −0.20% | +1.77% |
| 1 Week | +2.22% | +3.90% | −1.69% |
| 1 Month | +3.20% | +3.05% | +0.15% |
| 3 Months | −3.33% | +7.11% | −10.45% |
| 6 Months |